Safety profile of the viral vectors of attenuated fowlpox strain FP9 and modified vaccinia virus Ankara recombinant for either of 2 preerythrocytic malaria antigens, ME-TRAP or the circumsporozoite protein, in children and adults in Kenya.

Show other versions (1)

BACKGROUND: We are developing a heterologous prime-boost vaccine strategy against malaria. This approach uses sequential immunization with different vectors to deliver a common preerythrocytic malaria antigen. Preliminary evidence of efficacy and safety has been previously documented in studies fro...

תיאור מלא

מידע ביבליוגרפי
Main Authors:	Bejon, P, Peshu, N, Gilbert, S, Lowe, B, Molyneux, C, Forsdyke, J, Lang, T, Hill, A, Marsh, K
פורמט:	Journal article
שפה:	English
יצא לאור:	2006

פריטים דומים

Safety profile of the viral vectors of attenuated fowlpox strain FP9 and modified vaccinia virus Ankara recombinant for either of 2 preerythrocytic malaria antigens, ME-TRAP or the circumsporozoite protein, in children and adults in Kenya
מאת: Bejon, P, et al.
יצא לאור: (2006)

Immunogenicity of the candidate malaria vaccines FP9 and modified vaccinia virus Ankara encoding the pre-erythrocytic antigen ME-TRAP in 1-6 year old children in a malaria endemic area.
מאת: Bejon, P, et al.
יצא לאור: (2006)

A phase 2b randomised trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP among children in Kenya
מאת: Bejon, P, et al.
יצא לאור: (2006)

Safety and immunogenicity of the candidate malaria vaccines FP9 ME-TRAP and MVA METRAP in semi-immune adult males [MIM-OK-87312]
מאת: Kai, O, et al.
יצא לאור: (2005)

Safety of recombinant fowlpox strain FP9 and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteers.
מאת: Webster, D, et al.
יצא לאור: (2006)

Extended follow-up following a phase 2b randomized trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP among children in Kenya.
מאת: Bejon, P, et al.
יצא לאור: (2007)

Extended Follow-Up Following a Phase 2b Randomized Trial of the Candidate Malaria Vaccines FP9 ME-TRAP and MVA ME-TRAP among Children in Kenya
מאת: Bejon, P, et al.
יצא לאור: (2007)

Safety, immunogenicity, and efficacy of prime-boost immunization with recombinant poxvirus FP9 and modified vaccinia virus Ankara encoding the full-length Plasmodium falciparum circumsporozoite protein.
מאת: Walther, M, et al.
יצא לאור: (2006)

Safety, immunogenicity and efficacy studies of candidate malaria vaccines FP9 and MVA encoding ME-TRAP in Kenyan children [MIM-PB-224908]
מאת: Bejon, P, et al.
יצא לאור: (2005)

Extended follow-up following a phase 2b randomized trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP among children in Kenya.
מאת: Philip Bejon, et al.
יצא לאור: (2007-08-01)

Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara.
מאת: Webster, D, et al.
יצא לאור: (2005)

A DNA prime-modified vaccinia virus ankara boost vaccine encoding thrombospondin-related adhesion protein but not circumsporozoite protein partially protects healthy malaria-naive adults against Plasmodium falciparum sporozoite challenge.
מאת: Dunachie, S, et al.
יצא לאור: (2006)

Clinical development of Modified Vaccinia virus Ankara vaccines.
מאת: Gilbert, S
יצא לאור: (2013)

Clinical development of Modified Vaccinia virus Ankara vaccines
מאת: Gilbert, S
יצא לאור: (2013)

Safety and High Level Efficacy of the Combination Malaria Vaccine Regimen of RTS,S/AS01B With Chimpanzee Adenovirus 63 and Modified Vaccinia Ankara Vectored Vaccines Expressing ME-TRAP
מאת: Rampling, T, et al.
יצא לאור: (2016)

Evaluation of the efficacy of chad63-mva vectored vaccines expressing circumsporozoite protein and me-trap against controlled human malaria infection in malaria-naive individuals
מאת: Hodgson, SH, et al.
יצא לאור: (2014)

Improved Host Range Selection for Recombinant Modified Vaccinia Virus Ankara
מאת: Caroline Staib, et al.
יצא לאור: (2003-04-01)

Development of Modified Vaccinia Virus Ankara-Based Vaccines: Advantages and Applications
מאת: Olga Vladimirovna Orlova, et al.
יצא לאור: (2022-09-01)

Elements in the Development of a Production Process for Modified Vaccinia Virus Ankara
מאת: Volker Sandig, et al.
יצא לאור: (2013-11-01)

The Plasmodium falciparum cell-traversal protein for ookinetes and sporozoites as a candidate for preerythrocytic and transmission-blocking vaccines.
מאת: Espinosa, D, et al.
יצא לאור: (2016)

Evaluation of Plasmodium vivax Cell-Traversal Protein for Ookinetes and Sporozoites as a Preerythrocytic P. vivax Vaccine
מאת: Alves, E, et al.
יצא לאור: (2017)

Evaluation of the Efficacy of ChAd63-MVA Vectored Vaccines Expressing Circumsporozoite Protein and ME-TRAP Against Controlled Human Malaria Infection in Malaria-Naive Individuals.
מאת: Hodgson, S, et al.
יצא לאור: (2014)

Calculation of liver-to-blood inocula, parasite growth rates, and preerythrocytic vaccine efficacy, from serial quantitative polymerase chain reaction studies of volunteers challenged with malaria sporozoites.
מאת: Bejon, P, et al.
יצא לאור: (2005)

Transient Host Range Selection for Genetic Engineering of Modified Vaccinia Virus Ankara
מאת: C. Staib, et al.
יצא לאור: (2000-06-01)

The third generation modified vaccinia Ankara vaccine is effective in preventing the transmission of mpox
מאת: Mingwang Shen, et al.
יצא לאור: (2024-10-01)

Modified Vaccinia virus Ankara-based vaccines in the era of personalized immunotherapy of cancer
מאת: Kaïdre Bendjama, et al.
יצא לאור: (2017-09-01)

Hazard Characterization of Modified Vaccinia Virus Ankara Vector: What Are the Knowledge Gaps?
מאת: Malachy I. Okeke, et al.
יצא לאור: (2017-10-01)

Enhanced Expression of the <i>L1R</i> Gene of Vaccinia Virus by the tPA Signal Sequence Inserted in a Fowlpox-Based Recombinant Vaccine
מאת: Antonia Radaelli, et al.
יצא לאור: (2024-09-01)

IMMUNOBIOLOGICAL PROPERTIES OF FOWLPOX VIRUS CULTURAL VARIANTS
מאת: K. Yu. Fedoseyev, et al.
יצא לאור: (2018-04-01)

Avidity of anti-circumsporozoite antibodies following vaccination with RTS,S/AS01E in young children
מאת: Olotu, A, et al.
יצא לאור: (2014)

Avidity of anti-circumsporozoite antibodies following vaccination with RTS,S/AS01E in young children.
מאת: Ally Olotu, et al.
יצא לאור: (2014-01-01)

Immunodominance of poxviral-specific CTL in a human trial of recombinant-modified vaccinia Ankara.
מאת: Smith, C, et al.
יצא לאור: (2005)

Recombinant modified vaccinia virus Ankara efficiently restimulates human cytotoxic T lymphocytes in vitro.
מאת: Dorrell, L, et al.
יצא לאור: (2000)

Safety and immunogenicity of DNA/modified vaccinia virus ankara malaria vaccination in African adults.
מאת: Moorthy, V, et al.
יצא לאור: (2003)

A recombinant Modified Vaccinia virus Ankara expressing prME of tick-borne encephalitis virus affords mice full protection against TBEV infection
מאת: Mareike Kubinski, et al.
יצא לאור: (2023-04-01)

Construction of Deletion-knockout Mutant Fowlpox Virus (FWPV)
מאת: Stephen Laidlaw, et al.
יצא לאור: (2014-05-01)

Assessment of immunogenicity and efficacy of a Zika vaccine using modified vaccinia Ankara virus as carriers
מאת: López-Camacho, C, et al.
יצא לאור: (2019)

Ty virus-like particles, DNA vaccines and Modified Vaccinia Virus Ankara; comparisons and combinations.
מאת: Gilbert, S, et al.
יצא לאור: (1999)

New approaches for improving the immunogenicity of modified vaccinia virus Ankara as a recombinant vaccine vector
מאת: Alharbi, N
יצא לאור: (2014)

Assessment of Immunogenicity and Efficacy of a Zika Vaccine Using Modified Vaccinia Ankara Virus as Carriers
מאת: César López-Camacho, et al.
יצא לאור: (2019-11-01)